Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05870865 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

A Phase 2 study of Dermatitis, Atopic and Pruritus, sponsored by Formation Bio.

Completed
Registry status
Phase 2
Development phase
144
Enrollment target
20
Study locations

NCT05870865 is a Phase 2 study of Dermatitis, Atopic and Pruritus that has completed, run by Formation Bio. The registered enrollment target is 144 participants, below the 392-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05870865, a Phase 2 study of Dermatitis, Atopic and Pruritus, has completed, sponsored by Formation Bio.

COMPLETED
Registry status
Phase 2
Development phase
144 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: * What is the efficacy and safety of ASN008? * What is the impact of ASN008 on itch in patients with atopic dermatitis? Participants will be asked to apply topical ASN008, or matching vehicle (placebo containing no active drug), to their eczema lesions twice daily for 4 weeks. Researchers will compare 3 different doses of ASN008 and a matching vehicle group to see which group responds best.

Conditions Studied

Dermatitis, Atopic Pruritus

Interventions

  • DRUG ASN008
  • OTHER ASN008 Matching Vehicle

Study Locations (20)

California

  • TrialSpark Investigative Site 0123 - Beverly Hills
  • TrialSpark Investigative Site 0113 - Fremont
  • TrialSpark Investigative Site 0101 - Los Angeles

Florida

  • TrialSpark Investigative Site 0103 - Miami Lakes
  • TrialSpark Investigative Site 0129 - Miramar

Indiana

  • TrialSpark Investigative Site 0131 - Clarksville
  • TrialSpark Investigative Site 0109 - Indianapolis

Louisiana

  • TrialSpark Investigative Site 0108 - Baton Rouge
  • TrialSpark Investigative Site 0124 - Monroe

New York

  • TrialSpark Investigative Site 0115 - Kew Gardens
  • TrialSpark Investigative Site 0119 - New York

Arizona

  • TrialSpark Investigative Site 0106 - Scottsdale

Arkansas

  • TrialSpark Investigative Site 0118 - Hot Springs

Kentucky

  • TrialSpark Investigative Site 0112 - Louisville

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2023-05-03
Est. Completion 2023-12-28
Phase Phase 2

Sponsor

Formation Bio

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05870865

The ClinicalTrials.gov registry entry for NCT05870865 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 392-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (63% lower). The listed sponsor is Formation Bio, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which ASN008 is the first listed.

NCT05870865 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT05870865 about?

NCT05870865 is a clinical study titled "A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis". The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: * What is the efficacy and safety of ASN008? * What is the impact of ASN008 on itch in patients with atopic dermatitis? Participants will be asked to apply topical A...

What is the current status of trial NCT05870865?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2023-05-03. Estimated completion is 2023-12-28.

What conditions does trial NCT05870865 study?

This clinical trial studies the following conditions: Dermatitis, Atopic, Pruritus.

What interventions are being tested in trial NCT05870865?

The interventions under investigation include: ASN008 (DRUG), ASN008 Matching Vehicle (OTHER).

Who is sponsoring clinical trial NCT05870865?

This trial is sponsored by Formation Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05870865 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dermatitis, Atopic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dermatitis, Atopic

All registered trials for this condition

Pruritus

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.